Accelerate to discover

Homepage>Discover>Oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer at a single low dose

Dec 28, 2020

Radio-active sources have been used routinely for the preconditioning in humanized mouse models, but safety issues have...

EV imaging series: Using ONI super-resolution to characterize single-EVs

Dec 23, 2020

To date, researchers commonly use flow-based characterization methods, fluorescence imaging techniques and electron...

Don’t Let Waste Anesthetic Gases Harm You!

Dec 21, 2020

Many projects have been devoted to the study of the correlation between anesthetics and Alzheimer’s disease....

Advances in Leukemia research using shear flow and Bioflux system

Dec 10, 2020

Leukemia is a rare cancer with many subtypes. The production of abnormal leukocytes create disruptions in the immune...

Dec 30, 2020

Do you have our CellRad benchtop irradiator? It’s the only one on the market!

Dec 8, 2020

The CellRad is a smaller, simpler, safer, and more cost effective alternative to radioisotope or high-powered X-ray...

Dosimetric characterization of an X-ray irradiator for use with cells

Dec 4, 2020

This study aims to characterize an X-ray irradiator for use with cells using its internal parallel-plate ionization...

Modeling multiple myeloma-Bone Marrow interactions using Synthecon rotating-wall vessels

Dec 2, 2020

Multiple myeloma develops primarily inside the bone marrow microenvironment, that confers pro-survival signals and drug...

Dec 30, 2020

Bruker webinar: Ear evolution in fossil mammals

Nov 27, 2020

Hearing is just one of the functions aside of providing balance. Even juveniles obtain a fully developed ear region...

Show all topics (10)

Oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer at a single low dose

Oct 24, 2019

Trough this study we have seen that CF33 and CF33-Fluc are safe and efective in vitro and in vivo. Trough chimerization and high throughput screening, the novel virus have been created that requires lower doses to treat pancreatic cancer in a preclinical model. CF33-Fluc replication in non-injected, distant tumors halted tumor growth. Further studies in immune-competent models investigating the mechanisms of rapid tumor regression and viral spread to non-injected tumors following a low viral dose will enhance our understanding of how this novel virus targets and kills pancreatic cancer.

Do you want to learn more? Read this interesting article!

Scientific paper

Application

Get more info